ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VRAY ViewRay Inc

0.025
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
ViewRay Inc NASDAQ:VRAY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.025 0.027 0.0275 0 01:00:00

ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023

09/05/2023 9:10pm

PR Newswire (US)


ViewRay (NASDAQ:VRAY)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more ViewRay Charts.

DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of first quarter 2023 financial results.

ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars.

After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars."

About ViewRay®

ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Cision View original content:https://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-first-quarter-2023-financial-results-to-be-held-after-market-on-may-10-2023-301819978.html

SOURCE ViewRay, Inc.

Copyright 2023 PR Newswire

1 Year ViewRay Chart

1 Year ViewRay Chart

1 Month ViewRay Chart

1 Month ViewRay Chart